Picture of XORTX Therapeutics logo

XRTX XORTX Therapeutics Share Price

0.000.00%
ca flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-13.78%
3m-50.07%
6m-5.29%
1yr-65.66%
Volume Change (%)
10d/3m-93.38%
Price vs... (%)
52w High-67.37%
50d MA-17.37%
200d MA-28.94%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-91.58%
Return on Equity-57.92%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of XORTX Therapeutics EPS forecast chart

Profile Summary

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

Directors

Last Annual
December 31st, 2023
Last Interim
March 31st, 2024
Incorporated
May 31st, 2011
Public Since
September 30th, 2015
No. of Employees
3
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
ca flag iconTSX Venture Exchange
Shares in Issue
2,903,565

XRTX Share Price Performance

Upcoming Events for XRTX

XORTX Therapeutics Inc Annual Shareholders Meeting

Q2 2024 XORTX Therapeutics Inc Earnings Release

Q3 2024 XORTX Therapeutics Inc Earnings Release

Similar to XRTX

Picture of Arch Biopartners logo

Arch Biopartners

ca flag iconTSX Venture Exchange

Picture of biOasis Technologies logo

biOasis Technologies

ca flag iconTSX Venture Exchange

Picture of Covalon Technologies logo

Covalon Technologies

ca flag iconTSX Venture Exchange

Picture of Hemostemix logo

Hemostemix

ca flag iconTSX Venture Exchange

Picture of Innovotech logo

Innovotech

ca flag iconTSX Venture Exchange

FAQ